Pfizer CEO expects to submit children's COVID-19 vaccine data to FDA in days
Pfizer CEO Albert Bourla said Sunday that the company is planning to submit the data it compiled from COVID-19 vaccine trials for children between the ages of 5 and 11 to the Food and Drug Administration quite soon.
"It's a question of days, not weeks," he told ABC News' George Stephanopoulos on Sunday's edition of This Week.
Last week, Pfizer revealed that the vaccine it developed in tandem with BioNTech was safe and effective within the age group even with a smaller dose than the one that's been approved for ages 12 and up.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Once the FDA can review that information, the vaccine will be on track to become available for younger children, which will likely go a long way toward solidifying pandemic-related education policies throughout the U.S.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Magazine solutions - February 7, 2025
Puzzles and Quizzes Issue - February 7, 2025
By The Week US Published
-
Magazine printables - February 7, 2025
Puzzles and Quizzes Issue - February 7, 2025
By The Week US Published
-
Hands-on experiences that let travelers connect with the culture
The Week Recommends Sharpen your sense of place through these engaging activities
By Catherine Garcia, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published